KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Korsana Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$31.41−0.97 (-3.00%)
Close on Oct 19, 2026
- Market cap
- $133.52M
- P/E (TTM)
- –
- Dividend yield
- –
Korsana Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Agreement [Member] | $0 | $0 | $25.00K | $75.00K | $93.00K | $81.00K | $56.00K | $194.00K | $0 | $0 | – | -100.0% |
| Revenue from purchase agreement | – | – | $0 | $800.00K | – | – | $0 | $0 | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Korsana Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.